Mounjaro (Tirzepatide) Injection Pen – 10 mg

Introduction

The Mounjaro (Tirzepatide) 10 mg Injection Pen is a once-weekly prescription medicine for adults with type 2 diabetes. After completing the 2.5 mg starter dose and progressing through 5 mg and 7.5 mg, patients may advance to the 10 mg dose for stronger blood sugar control and continued weight management. Developed by Eli Lilly, Mounjaro is the world’s first dual GIP and GLP-1 receptor agonist, offering an innovative approach to diabetes treatment and metabolic health.

Who Should Use the 10 mg Pen?

The 10 mg strength is intended for:

• Adults with type 2 diabetes mellitus requiring greater glycaemic control.

• Patients who have tolerated lower strengths (2.5, 5, and 7.5 mg).

• Individuals who need ongoing weight management support alongside diabetes care.

This dose is not a starting dose. It is a progressive step for patients who have safely adjusted to lower doses and need more powerful therapy.

How Mounjaro 10 mg Works

Mounjaro’s active ingredient, tirzepatide, works by activating two incretin hormone pathways:

• GLP-1 receptor agonist: Encourages insulin release when glucose is high, reduces glucagon, slows digestion, and curbs appetite.

• GIP receptor agonist: Improves insulin sensitivity and enhances the body’s ability to process glucose and fats.

By combining these mechanisms, Mounjaro helps lower HbA1c levels, reduces weight, and supports long-term cardiometabolic health.

Benefits of Mounjaro 10 mg

1. Stronger Blood Sugar Control

• Helps reduce fasting and post-meal glucose.

• Works in synergy with the body’s natural insulin response.

2. Continued Weight Reduction

• Reduces appetite and food cravings.

• Promotes sustainable weight loss when combined with lifestyle changes.

3. Heart and Metabolic Health

• Improves cholesterol levels.

• May lower blood pressure and inflammation markers.

4. Simple Weekly Injection

Each pen contains a single prefilled dose, designed for once-weekly use. No daily injections are required.

Dosing and Administration

• Initiation: 2.5 mg weekly for 4 weeks.

• Escalation: 5 mg, then 7.5 mg, before reaching 10 mg.

• Ongoing therapy: 10 mg once weekly, adjusted as needed.

• Higher strengths (12.5 mg or 15 mg) may follow if required.

How to inject:

• Subcutaneous injection into abdomen, thigh, or upper arm.

• Rotate injection sites each week.

• Can be taken any time of day, with or without meals.

1 pen = 1 dose = 1 week. A month’s therapy typically requires 4 pens.

Side Effects

Common:

• Nausea, vomiting, diarrhoea

• Decreased appetite

• Constipation

Less common but serious:

• Pancreatitis (severe abdominal pain)

• Gallbladder disorders

• Kidney complications (from dehydration)

• Severe allergic reactions

⚠️ Not suitable for patients with a history of medullary thyroid carcinoma or MEN 2.

Storage Instructions

• Keep refrigerated (2°C–8°C).

• Do not freeze.

• Can be stored at room temperature (below 30°C) for up to 21 days.

• Protect from light; store in original packaging.

Why Choose the 10 mg Pen?

• Ideal for patients progressing beyond 7.5 mg.

• Provides stronger therapeutic effects.

• Supports long-term improvements in blood sugar and body weight.

• Simple, discreet, once-weekly pen for convenient use.

• Backed by clinical trials in the SURPASS program.

Conclusion

The Mounjaro (Tirzepatide) 10 mg Injection Pen is an important step for patients managing type 2 diabetes who need enhanced glycaemic control and continued weight support. With its unique dual incretin mechanism, once-weekly dosing, and proven clinical benefits, Mounjaro 10 mg helps patients move closer to their health goals in diabetes care and beyond.